Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Growing at a Significant Rate in the Forecast Period 2018-2025

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market According to Data Bridge Market Research new Market report,By Product Type (Blood Pressure Monitoring Devices, Pulmonary Pressure Monitoring Devices, Intracranial Pressure Monitoring Devices), By Application (Neurodegenerative Disorders, Autoimmune Diseases, Cancer, Tumors, Cardiovascular Diseases), By End-User (Hospitals and Ambulatory Surgical Centre), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast is projected to reach USD 113.04 billion by 2025, at a CAGR of 3.7% during the forecast period of 2018 to 2025.

Access Full Report: https://databridgemarketresearch.com/reports/global-autologous-stem-cell-and-non-stem-cell-based-therapies-market/

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Stem cell and non-stem cell based therapies are considered to be an effective and safer technologies as compared to the existing transplant technologies such as allogeneic and xeno transplants. These kind of therapies do not involve the usage of foreign organism cells which results in significant reduction in transplant associated risks of immune reactions, disease transmission and HLA incompatibility.

Autologous stem-cell transplantation is the transplantation in which the undifferentiated cells are taken from a person, accumulated, and given back to the same person later.

According to a journal, stem cell therapies in clinical trials: progress and challenges published on science direct states that,  in entire area of cell therapies in 2014, 70% of trials were sponsored by academic institutions and 30% by companies (Bersenev, 2015). A combination of public and private funding was strongly encouraged in the funding of translation and clinical stem cell trials for sustained capacity by the Californian institute for regenerative medicine.

The U.S. based company named advanced cell technology and the South Korean company CHA Biotech Ltd. have announced the formation of a new company that will be the product of a joint venture. The new company is to be known as “stem cell and regenerative medicine international” and will be headquartered in Worcester, Massachusetts. In this new partnership, both companies will collaborate together as one new company in the further development and commercialization of proprietary stem cell technology and cell-based clinical therapies.

Segmentation: Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

The global market for Autologous Stem Cell and Non-Stem Cell Based Therapies by the following sub-categories is presented

  • By Product Type

    • Blood Pressure Monitoring Devices
    • Pulmonary Pressure Monitoring Devices
    • Intracranial Pressure Monitoring Devices

  • By Application

    • Eurodegenerative Disorders
    • Autoimmune Diseases
    • Cancer
    • Tumours
    • Cardiovascular Diseases

  • By End-User

    • Hospitals
    • Ambulatory Surgical Centre

  • By Geography

    • North America
    • South America
    • Europe
    • Asia-Pacific
    • Middle East and Africa

FACTORS DRIVING GROWTH IN GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET:

Growing prevalence of fatal neurodegenerative, cardiovascular and cancer diseases:

When the cells of the nervous system begin to deteriorate, there is an occurrence of disease called neurodegenerative disease. According to the Harvard neurodiscovery center, today neurodegenerative diseases strike primarily in mid- to late-life, almost 5 million Americans suffer from Alzheimer’s disease, 40,000 from multiple sclerosis, 1 million from Parkinson’s and 30,000 from amyotrophic lateral sclerosis. By 2030, 1 in every 5 individuals in America will be above 65 years of age, and if left unchecked 30 years from now, it is expected that 12 million Americans will suffer from neurodegenerative diseases.

According to a report by national cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the United States alone. Moreover, it was noted that around 595,690 people died from the disease in the same year. According to the national cancer institute study (2011-2015) the combined rate of cancer in men and women is 439.2 per 100,000. And the combined rate of cancer death in men and women is 163.5 per 100,000. According to the worldwide cancer statistics 2012, there were 14.1 million new cases of cancer worldwide. The number of deaths due to cancer was 8.2 million. By 2026, the new cases of cancer are expected to reach 23.6 million mark.

Due to the growth in ageing population, the cases of cancer as well as neurodegenerative disease is expected to achieve a growing mark in future. Hence, providing this market an excellent platform in future.

Technological advancements and increase in demand for autologous stem cell and non-stem cell primarily based therapies:

The Sanford stem cell clinical center at the University of California, San Diego, in September 2014, announced the launch of a groundbreaking clinical trial to assess the safety of neural stem cell–based therapies in patients with chronic spinal cord injury. As per the researcher, the transplanted stem cells will develop into new neurons that replace severed or lost nerve connections and restore at least some motor and sensory function.

Autologous stem cell and non-stem cell based therapies are likely to become one of the preferred treatments for cancer. The main advantage of this therapy over chemotherapy is that it allows patients to have normal bone marrow, which gets destroyed in chemotherapy. Hence, the demand for this type of therapy is on the rise, providing this market an inclining rate in future.

Some of the major market players in this market are U.S. Stem Cell, Inc, Cytori Therapeutics Inc, Microbot Medical Inc., pluristem, Athersys Inc, NurOwn, Caladrius, Neuralstem, Inc., TiGenix, Dendreon Pharmaceuticals LLC, Regenexx, Regeneus Ltd, Fibrocell Science, Inc, ovance Biotherapeutics, Inc. Orgenesis Inc., Opexa Therapeutics, Inc,.

Browse Related Reports:      

Global Immunoassay Reagents and Devices Market By Product (Reagents, Analyzers, Software, Services), By Technique (ELISA, RIA, CLIA, Others), By Application (Infectious Diseases, Endocrinology, Cardiology, Oncology, Others), By End User (Hospitals, Labs, Biotechnology Industry, Pharmaceutical Industry, Others), By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024.

https://databridgemarketresearch.com/reports/global-immunoassay-reagents-and-devices-market/

Global Radio Immunoassay (RIA) Reagents and Devices Market By Product Type, End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast to 2024.

https://databridgemarketresearch.com/reports/global-radio-immunoassay-ria-reagents-and-devices-market/

Global Clinical Chemistry Analyzer Market By Product type (Consumables and Accessories (Reagents, Assay Kits, Microplates, Accessories), Instruments (Spectrophotometers, Flow Cytometers, Hematology Analyzers, Cell Counters), By End-User (Hospitals, Diagnostic Centers, Research Institutions, Pharmaceutical and Biotechnology Companies), By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024.

https://databridgemarketresearch.com/reports/global-clinical-chemistry-analyzer-market/